Neuphoria Therapeutics (BNOXN) Ratios
Neuphoria Therapeutics Ratios
MX:BNOXN's free cash flow for Q4 2026 was $-12.34B. For the 2026 fiscal year, MX:BNOXN's free cash flow was increased by $0.00 and operating cash flow was $1.19M. See a summary of the company’s cash flow.
| Ratios | Jun 26 | Jun 25 | Jun 24 | Jun 23 | Jun 22 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 27.85 | 3.56 | 3.45 | 4.87 | 12.46 |
| Quick Ratio | 27.85 | 3.56 | 3.45 | 4.87 | 12.46 |
| Cash Ratio | 26.26 | 3.37 | 3.29 | 4.42 | 10.00 |
| Solvency Ratio | -0.00 | 0.02 | -2.19 | -4.42 | -3.77 |
| Operating Cash Flow Ratio | -16.33 | 12.04 | -3.83 | -5.40 | -6.48 |
| Short-Term Operating Cash Flow Coverage | -359676.05 | 1552.03 | -443.27 | -100.57 | 0.00 |
| Net Current Asset Value | $ 16.96B | $ 8.29M | $ 3.04M | $ 4.13M | $ 22.99M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.00 | 0.01 | 0.01 | 0.01 | 0.01 |
| Debt-to-Equity Ratio | 0.00 | 0.01 | 0.02 | 0.02 | 0.01 |
| Debt-to-Capital Ratio | 0.00 | 0.01 | 0.02 | 0.02 | 0.01 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.17 | 1.50 | 1.58 | 1.32 | 1.15 |
| Debt Service Coverage Ratio | -262.29 | 0.04 | -670.31 | -214.25 | -1175.02 |
| Interest Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | -1547.24 |
| Debt to Market Cap | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.01 | 0.14 | 0.00 | 0.00 | 0.00 |
| Net Debt to EBITDA | 2171.68 | 45.83 | 0.55 | 0.36 | 0.81 |
| Profitability Margins | |||||
| Gross Profit Margin | 43.54% | 95.76% | 0.00% | 0.00% | 0.00% |
| EBIT Margin | -835.53% | -7.21% | 0.00% | 0.00% | -10506.50% |
| EBITDA Margin | -779.07% | -2.98% | 0.00% | 0.00% | -10085.68% |
| Operating Profit Margin | -835.53% | -7.21% | 0.00% | 0.00% | -10292.00% |
| Pretax Profit Margin | -1157.51% | -5.35% | 0.00% | 0.00% | -10523.25% |
| Net Profit Margin | -1145.66% | -2.36% | 0.00% | 0.00% | -8253.62% |
| Continuous Operations Profit Margin | -1145.66% | -2.36% | 0.00% | 0.00% | -8253.62% |
| Net Income Per EBT | 98.98% | 44.11% | 99.44% | 97.44% | 78.43% |
| EBT Per EBIT | 138.54% | 74.22% | 87.07% | 99.82% | 102.25% |
| Return on Assets (ROA) | -0.05% | -0.85% | -83.88% | -111.62% | -51.05% |
| Return on Equity (ROE) | -0.05% | -1.28% | -132.61% | -147.75% | -58.58% |
| Return on Capital Employed (ROCE) | -0.04% | -3.05% | -112.45% | -126.66% | -67.11% |
| Return on Invested Capital (ROIC) | -0.03% | -1.34% | -111.10% | -122.74% | -52.50% |
| Return on Tangible Assets | -0.06% | -1.61% | -171.92% | -227.24% | -78.26% |
| Earnings Yield | -70.02% | -3.21% | -1.87% | -0.45% | -0.24% |
| Efficiency Ratios | |||||
| Receivables Turnover | 1.44 | 1309.80 | 0.00 | 0.00 | 0.06 |
| Payables Turnover | 1.72 | 0.38 | 0.44 | 0.70 | 0.00 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.00 | 97.74 | 0.00 | 0.00 | 0.60 |
| Asset Turnover | 0.00 | 0.36 | 0.00 | 0.00 | 0.01 |
| Working Capital Turnover Ratio | 0.00 | 1.21 | 0.00 | 0.00 | 0.01 |
| Cash Conversion Cycle | 40.57 | -965.48 | -825.20 | -520.83 | 6129.89 |
| Days of Sales Outstanding | 252.86 | 0.28 | 0.00 | 0.00 | 6129.89 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 212.29 | 965.76 | 825.20 | 520.83 | 0.00 |
| Operating Cycle | 252.86 | 0.28 | 0.00 | 0.00 | 6129.89 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -2810.07 | 47.59 | -0.10 | -0.08 | -0.13 |
| Free Cash Flow Per Share | -2810.07 | 47.59 | -0.10 | -0.08 | -0.13 |
| Dividend Paid and CapEx Coverage Ratio | -3088268500.00 | 0.00 | 0.00 | -39433370.83 | -14092.09 |
| Capital Expenditure Coverage Ratio | -3088268500.00 | 0.00 | 0.00 | -39433370.83 | -14092.09 |
| Operating Cash Flow Coverage Ratio | -359676.05 | 340.99 | -53.83 | -38.23 | -31.37 |
| Operating Cash Flow to Sales Ratio | -10520.73 | 4.93 | 0.00 | 0.00 | -53.85 |
| Free Cash Flow Yield | -64303.69% | 670.23% | -1.18% | -0.20% | -0.16% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -1.43 | -30.87 | -53.48 | -224.01 | -412.44 |
| Price-to-Sales (P/S) Ratio | 16.36 | 0.74 | 0.00 | 0.00 | 34041.66 |
| Price-to-Book (P/B) Ratio | 0.00 | 0.40 | 70.92 | 330.97 | 241.63 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -0.00 | 0.15 | -84.49 | -492.49 | -632.06 |
| Price-to-Operating Cash Flow Ratio | -0.00 | 0.15 | -84.49 | -492.49 | -632.10 |
| Price-to-Earnings Growth (PEG) Ratio | -0.00 | -0.24 | 1.30 | -7.28 | -13.75 |
| Enterprise Value Multiple | 2169.58 | 21.11 | -54.99 | -224.71 | -336.72 |
| Enterprise Value | -19.85B | -9.84M | 1.23B | 4.84B | 9.44B |
| EV to EBITDA | 2169.58 | 21.11 | -54.99 | -224.71 | -336.72 |
| EV to Sales | -16902.47 | -0.63 | 0.00 | 0.00 | 33960.29 |
| EV to Free Cash Flow | 1.61 | -0.13 | -83.65 | -491.70 | -630.55 |
| EV to Operating Cash Flow | 1.61 | -0.13 | -83.65 | -491.70 | -630.59 |
| Tangible Book Value Per Share | 3857.99 | 5.20 | 0.02 | 0.04 | 0.21 |
| Shareholders’ Equity Per Share | 5596.00 | 17.79 | 0.12 | 0.12 | 0.35 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.01 | 0.56 | 0.01 | 0.03 | 0.22 |
| Revenue Per Share | 0.27 | 9.64 | 0.00 | 0.00 | 0.00 |
| Net Income Per Share | -3.06 | -0.23 | -0.15 | -0.18 | -0.20 |
| Tax Burden | 0.99 | 0.44 | 0.99 | 0.97 | 0.78 |
| Interest Burden | 1.39 | 0.74 | 1.00 | 1.00 | 1.00 |
| Research & Development to Revenue | 3019.53 | 0.58 | 0.00 | 0.00 | 60.69 |
| SG&A to Revenue | 6335.76 | 0.50 | 0.00 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 299.45 | 10.47 | 0.00 | 0.00 | 7.00 |
| Income Quality | 0.92 | -0.21 | 0.95 | 0.68 | 1.00 |
Currency in AUD
